Table 1 Baseline characteristics
Parameter | Value (n = 29) |
|---|---|
Female, n (%) | 10 (34) |
Age, years | 66.6 ± 11.0 |
Age > 65 years, n (%) | 16 (55) |
Body mass index, kg/m2 | 32.4 ± 6.1 |
Body mass index ≥ 30 kg/m2, n (%) | 19 (66) |
Creatinine, mg/dl | 1.0 (0.8–1.2) |
Estimated glomerular filtration rate, ml/min/1.73 m2 | 68.8 ± 25.7 |
History of deep vein thrombosis, n (%) | 8 (28) |
History of PE, n (%) | 4 (14) |
History of chronic heart failure, n (%) | 4 (14) |
History of cancer, n (%) | 4 (14) |
Active cancer, n (%) | 6 (21) |
Major surgery within four weeks, n (%) | 2 (7) |
Contraindication to lytics, n (%) | 3 (10) |
Vasopressor required, n (%) | 5 (17) |
PESI score | 121 ± 38 |
Simplified PESI (sPESI) score | 2.3 ± 1.3 |
sPESI low risk (sPESI = 0), n (%) | 1 (3) |
sPESI high risk (sPESI ≥ 1), n (%) | 28 (97) |
Concomitant deep vein thrombosis, n (%) | 24 (83) |
Proximal (over the knee), n (%) | 17 (59) |
Distal (below knee), n (%) | 15 (52) |
Both (proximal & distal), n (%) | 8 (28) |
Bilateral, n (%) | 5 (17) |
Biomarkers | |
Positive biomarkersa, n (%) | 28 (97) |
Hs-troponin T, pg/mL | 80 (55–128) |
NT-proBNP, pg/mL | 2327 (1340–4166) |
PE risk stratification | |
High risk PE, n (%) | 5 (17) |
Intermediate-high PE, n (%) | 22 (76) |
Intermediate-low PE, n (%) | 1 (3) |
Low risk PE, n (%) | 1 (3) |